Cabotegravir Oral Route

How is Cabotegravir Oral Route dosed?

For short-term treatment of HIV infection, the recommended dose of cabotegravir is 30 milligrams (mg) in combination with 25 mg of rilpivirine once a day for at least 28 days. If a patient misses or plans to miss a scheduled monthly injection of Cabenuva by more than 7 days, they should take 30 mg in combination with 25 mg of rilpivirine once a day. The dose for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection is also 30 mg once a day. The dose for children younger than 12 years of age or weighing less than 35 kg should be determined by a doctor.

What is the dosage form of Cabotegravir Oral Route?

The oral dosage form of cabotegravir is available in tablets.

What medications are contraindication with Cabotegravir Oral Route?

Cabotegravir oral route should not be used together with seizure medicines (carbamazepine, oxcarbazepine, phenobarbital, phenytoin, Dilantin, Tegretol, Trileptal) or medicines to treat tuberculosis (rifampin, rifapentine, Priftin, Rifadin, Rimactane). Using these medicines together may make cabotegravir less effective. Always consult your doctor before combining medications.

How is Cabotegravir Oral Route administered?

Cabotegravir oral route is administered in the form of tablets for both short-term treatment of HIV infection as part of Cabenuva and for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection as part of Apretude. The dosage for adults and children weighing 35 kg or more is 30 milligrams (mg) once a day, taken in combination with 25 mg of rilpivirine. For children younger than 12 years of age or weighing less than 35 kg, the use and dose are determined by a doctor.

What are common precautions when taking Cabotegravir Oral Route?

Common precautions when taking cabotegravir oral route include:

  1. Taking the medicine with food when combined with rilpivirine.
  2. Avoiding taking antacids containing aluminum, magnesium, or calcium within 2 hours before or 4 hours after taking cabotegravir.
  3. Following the dosage instructions given by your doctor, as it may vary based on individual factors such as age, weight, medical history, and other medications being taken.
  4. Monitoring for any potential side effects, such as fever, headache, joint pain, sleepiness, or unusual drowsiness, and consulting with your healthcare professional if they persist or worsen.
  5. Informing your doctor if you are breastfeeding or plan to breastfeed, as there is limited information available on the safety of the medication during breastfeeding. Remember to always follow your doctor's instructions and report any concerns or side effects to your healthcare professional.